InSite Vision to Webcast 2004 Annual Meeting of Stockholders
ALAMEDA, Calif., May 27 /PRNewswire-FirstCall/ -- InSite Vision Incorporated
(AMEX:ISV), an ophthalmic therapeutics, diagnostics and drug- delivery company,
today announced that its annual meeting of stockholders will be broadcast live
over the Internet on June 1, 2004 at 1:00 p.m. Eastern Time. Those listening to
the meeting via the live Internet broadcast will not have the opportunity to
ask questions during the meeting.
What: InSite Vision Annual Meeting of Stockholders When: 1:00 p.m. ET, June 1, 2004 Where: http://www.videonewswire.com/event.asp?id=22946 How: Live over the Internet -- Simply log on to the Web at the
address above.
Contact: Brandi Floberg
Lippert/Heilshorn & Associates, Inc. (310) 691-7100
Following the vote on proxy items and the completion of the Annual Meeting,
InSite Vision's management will present an update on the Company, including
progress towards the initiation of Phase 3 clinical trials with its lead drug
candidate ISV-401.
InSite Vision is an ophthalmic products company focused on ocular infections,
glaucoma and retinal diseases. The Company's lead product is ISV-401, which
targets infections of the eye. In the area of glaucoma, the Company conducts
genomic research using TIGR and other genes. A portion of this research has
been incorporated into the Company's OcuGene(R) glaucoma genetic test for
disease management, as well as ISV-205, its novel glaucoma therapeutic.
ISV-205 uses InSite Vision's proprietary DuraSite(R) drug- delivery technology,
which also is incorporated into the ocular infection product ISV-401, and
InSite Vision's retinal disease program. Additional information can be found
at http://www.insitevision.com/.
If you are unable to participate during the live webcast, the webcast will be
archived beginning approximately two hours following the event for 90 days on
the Company's Web site http://www.insitevision.com/. To access the replay, go
to the "Investor Relations" section and click on the InSite Vision 2004 Annual
Meeting icon.
(Minimum Requirements to listen to broadcast: Windows Media Player software,
downloadable free from http://www.videonewswire.com/event.asp?id=22946, and at
least a 28.8Kbps connection to the Internet. If you experience problems
listening to the broadcast, send an e-mail to .) This press release and the 2004 Annual Meeting of Stockholders webcast may
contain, among other things, certain statements of a forward-looking nature
relating to future events or the future business performance or future
financing of InSite Vision such as the timing of initiation and completion of
future clinical trials and the filing of an NDA for ISV-401, and the timing and
probability of the final closing of the Company's announced $16.5 million
equity financing. Such statements entail a number of risks and uncertainties,
including but not limited to: InSite Vision's ability to obtain stockholder
approval and satisfy the other conditions to closing on the final tranche of
its recently announced equity financing, InSite Vision's immediate need for
significant additional funding to continue its operations in the event that it
does not consummate the final closing, InSite's ability to commence and
complete future clinical trials for ISV-401 and file an NDA for such product
candidate, the results of its clinical trials, particularly for ISV-401, the
effects of its expense control activities on its operations and product
development; its ability to obtain regulatory approval and market acceptance of
its products, OcuGene glaucoma genetic test, ISV-401 and ISV-205; InSite
Vision's ability to maintain and develop additional collaborations and
commercial agreements with corporate partners, including those with respect to
ISV-401 and ISV-205; its reliance on third parties for the development,
marketing and sale of its products; the initiation and results of preclinical
and clinical studies; its ability to adequately protect its intellectual
property; and determinations by the U.S. Food and Drug Administration,
including those with respect to OcuGene, ISV-401 and ISV-205. Readers of this
release and viewers of the webcast should carefully review and consider the
discussion of risk factors detailed in InSite Vision's filings with the
Securities and Exchange Commission, including its annual report on Form 10-K
for the 2003 fiscal year, and Form 10-Q for the quarter ended March 31, 2004. Any projections in this release or webcast are based on limited information
currently available to InSite Vision, which is subject to change. Although any
such projections and the factors influencing them will likely change, InSite
Vision undertakes no obligation to update the information. Such information
speaks only as of the date of this release or webcast. Actual events or
results could differ materially and no reader of this release or listener to
the webcast should assume later that the information provided today or during
the webcast is still valid.
COMPANY CONTACTS:
InSite Vision Incorporated
S. Kumar Chandrasekaran, CEO
Sandra Heine, Director of Finance
(510) 865-8800
http://www.insitevision.com/ INVESTOR CONTACTS:
Lippert/Heilshorn & Associates, Inc. Bruce Voss ()
Jody Cain ()
(310) 691-7100
http://www.lhai.com/ MEDIA CONTACTS:
Lippert/Heilshorn & Associates, Inc. Chenoa Taitt ()
Michael Hopkins ()
(212) 838-3777
http://www.lhai.com/ http://www.videonewswire.com/event.asp?id=22946DATASOURCE: InSite Vision
Incorporated CONTACT: S. Kumar Chandrasekaran, CEO, or Sandra Heine, Director of Finance, of InSite Vision Incorporated, +1-510-865-8800; or Investors, Bruce Voss, , or Jody Cain, , +1-310-691-7100, or Media, Chenoa Taitt, , or Michael Hopkins, , +1-212-838-3777, all of Lippert/Heilshorn & Associates, Inc., for InSite Vision Incorporated Web site: http://www.lhai.com/ Web site: http://www.insitevision.com/
|